Everything Lupus: Resource Hub

Default Image

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

Read
Default Image

Dr. Samir Gupta explains how the four COVID-19 vaccines now approved in Canada work and why efficacy rates aren’t the most important number to look at.

Read
Default Image

Six Bio-Ethicists on Ontario Government’s “Bioethics Table” Confirm Ongoing Concerns Raised by Disability Organizations regarding the Discriminatory and Secret Plans for the Triaging of Critical Care

Read
Default Image

LUPUS AND COVID-19 VACCINATION WAIT TIMES

Read
Default Image

COVID-19: PROOF OF VACCINATION

Read
Default Image

One Catalyst Award for a total of $40,000 CDN to fund one project for a term of one year (Current year)

Read
Default Image

Non-pharmacological interventions to improve the socioeconomic lives of individuals with SLE

Read
Default Image

Immune and inflammatory mechanisms critical to the development of SLE, with a focus on RIPK3-dependent pathways

Read
Default Image

COVID-19: PROOF OF VACCINATION

Read
Default Image

Phenotyping SLE based on disease course: remitting-relapsing, persistently active and monophasic

Read
Default Image

NATIONAL ADVISORY COMMITTEE OF IMMUNIZATION (NACI) RAPID RESPONSE: ADDITIONAL DOSE OF COVID-19 VACCINE IN IMMUNOCOMPROMISED INDIVIDUALS FOLLOWING 1- OR 2- DOSE PRIMARY SERIES

Read
Default Image

If you’re moderately to severely immunocompromised due to disease or treatment,

Read